Old Web
English
Sign In
Acemap
>
authorDetail
>
Matthias Calamia
Matthias Calamia
Utrecht University
Medicine
Cancer research
Ceritinib
ALK inhibitor
Brigatinib
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM).
2021
Journal of Clinical Oncology
Neda AlRawashdh
Briana Choi
Mavis Obeng-Kusi
Matthias Calamia
Ali McBride
Ivo Abraham
Show All
Source
Cite
Save
Citations (1)
Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).
2021
Journal of Clinical Oncology
Briana Choi
Nimer S. Alkhatib
Hala Halawah
Matthias Calamia
Dexter Gulick
AlMothana Manasrah
Odai Alkhdour
Ali McBride
Ivo Abraham
Show All
Source
Cite
Save
Citations (0)
Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second-line treatment.
2021
Journal of Clinical Oncology
Nimer S. Alkhatib
Briana Choi
Hala Halawah
Matthias Calamia
Dexter Gulick
AlMothana Manasrah
Odai Alkhdour
Ali McBride
Ivo Abraham
Show All
Source
Cite
Save
Citations (0)
Polatuzumab vedotin-bendamustine-rituximab (PBR) versus tafasitamab-lenalidomide (TafaL) in ASCT-transplant ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Economic evaluation including novel metrics.
2021
Journal of Clinical Oncology
Matthias Calamia
Ali McBride
Ivo Abraham
Show All
Source
Cite
Save
Citations (0)
1